The Movement Disorder Society,
U.S. Department of Defense, the
National Institutes of Health, and
professional associations and
patient voluntary organizations.
World Parkinson Congress Inc.
710 West 168th Street, 3rd Floor
New York, NY 10032 USA
info@worldpdcongress.org
Copyright © 2006
Industry Supported Educational Sessions
World Parkinson Congress 2006
Educational Sessions*
Wednesday, February 22, 2006
Washington, DC Convention Center
8:30 a.m. to 6:15 p.m.
Location: Ballroom B, 2nd Floor
The World Parkinson Congress is pleased to announce that the day of the Opening Ceremony a number of Educational Sessions* will be held for registrants of the Congress.
These Educational Sessions will provide the latest information regarding research and treatment options for Parkinson's disease. Admission to these sessions will be by delegate name badge; no tickets will be required.
Please bookmark this page on the WPC website and visit it often to get the latest update on the session titles, times and room locations. The program is being created at this time and will be posted on this page once it is complete. A separate Industry Supported Educational Session program will also be sent by mail.
*Educational Sessions are supported through unrestricted educational grants from: Novartis Pharma AG/Orion Pharma; Boehringer Ingelheim; Schwarz Pharma; GlaxoSmithKline; Kyowa Pharmaceuticals; Teva Pharmaceutical Industries Ltd., Teva Neuroscience, Lundbeck and Eisai; and Valeant Pharmaceuticals.
8:30 a.m. - 9:30 a.m.
Session Title: Novel Perspectives on Adjunctive Therapies in Parkinson's Disease
Chair: Wolfgang Oertel
Topic 1: Novel perspectives on the use of Tolcapone - C. Warren Olanow
Topic 2: Novel delivery of Selegiline - Ray Watts
Panel
Supported through an unrestricted education grant from Valeant Pharmaceuticals.
9:45 a.m. - 10:45 a.m.
Session Title: MAO Inhibition: State of the Art
Chair: Stanley Fahn
Topic 1: MAO-B inhibitors: symptomatic effects in the treatment of early and advanced PD - Olivier Rascol
Topic 2: MAO-B inhibitors do they have disease modifying effects? - Andrew Siderowf
Panel
Supported through an unrestricted education grant from Teva Pharmaceutical Industries Ltd., Teva Neuroscience, Lundbeck and Eisai
11:00 a.m. - 12:00 p.m.
Session Title: Drugs in the Pipeline
Chair: Joseph Jankovic
Topic 1: Non-dopaminergic drugs in the pipeline - Peter Jenner
Topic 2: Clinical trials with A2A antagonists - Mark Stacy
Panel
Supported through an unrestricted education grant from Kyowa Pharmaceutical, Inc.
12:15 p.m. - 1:15 p.m.
Session Title: Patch Delivery
Chair: Anthony Lang
Topic 1: Novel methods for drug delivery - José Obeso
Topic 2: Rotigotine - patch delivery of a dopamine agonist - Cheryl Waters
Panel
Supported through an unrestricted education grant from Schwarz Pharma
1:15 p.m. - 1:45 p.m. LUNCH BREAK
1:45 p.m. - 2:45 p.m.
Session Title: RLS and PD: Is There a Relationship
Chair: Kapil Sethi
Topic 1: RLS and PD - Cynthia Comella
Topic 2: Treatment of RLS - Eduardo Tolosa
Panel
Supported through an unrestricted education grant from GlaxoSmithKline
3:00 p.m. - 4:00 p.m.
Session Title: Non-motor Features of PD
Chair: Christopher Goetz
Topic 1: An overview of non-motor features of PD - Nir Giladi
Topic 2: Treatment of non-motor features - Matthew Stern
Panel
Supported through an unrestricted education grant from Boehringer Ingelheim Pharmaceuticals, Inc.
4:15 p.m. - 5:15 p.m.
Session Title: Levodopa: the Past, the Present and the Future
Chair: Anthony Lang
Topic 1: Levodopa - history, strengths and weaknesses - Andrew Lees
Topic 2: Evidence for and against the concept of CDS in PD - C. Warren Olanow
Topic 3: Attempts to obtain CDS with Levodopa formulations - Fabrizio Stocchi
Panel
Supported through an unrestricted education grant from Novartis Pharma AG/Orion Pharma